RT Journal Article SR Electronic T1 Molecules in cancer immunotherapy: benefits and side effects JF Journal of Clinical Pathology JO J Clin Pathol FD BMJ Publishing Group Ltd and Association of Clinical Pathologists SP 20 OP 24 DO 10.1136/jclinpath-2018-205370 VO 72 IS 1 A1 Adrian C Bateman YR 2019 UL http://jcp.bmj.com/content/72/1/20.abstract AB This mini review describes some of the key interactions between cancer cells and the immune system. This includes the concept of tumour cell immunosurveillance, mechanisms of immune evasion by tumour cells and some of the novel immunology-based anticancer therapies that have recently been introduced. The latter are also set into the context of the enlarging spectrum of immunohistochemistry-based and molecular testing that can now be performed on formalin-fixed and paraffin-embedded tissues for predicting response to both well-established and newly developed agents. The emerging field of cancer immunotherapy requires and encourages close working between cellular and molecular pathology and clinical cancer treatment, while providing new hope for patients with cancers that may not have responded to conventional oncological treatments.